BCL2 and non-Hodgkin lymphoma: However, exclusive targeting of BCL-2 with venetoclax in relapsed or refractory non-Hodgkin lymphoma (NHL) patients has yielded only a modest 18% overall response rate with a 1-month median progression-free survival11.